Aspergillus Allergy: ABPA, SAFS, and When Shots Aren't the Answer
Aspergillus fumigatus causes three distinct allergic conditions — simple IgE sensitization (25% of asthmatics), severe asthma with fungal sensitization (SAFS), and allergic bronchopulmonary aspergillosis (ABPA, affecting ~11.3% of asthmatics) — each requiring a different treatment approach. SCIT is not first-line for any of them; ABPA is generally an exclusion criterion for SCIT, with omalizumab, oral corticosteroids, and itraconazole as evidence-based therapies.
Aspergillus Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to aspergillus — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of aspergillus allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of aspergillus immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of aspergillus extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for aspergillus allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing aspergillus extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription aspergillus immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat aspergillus allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Aspergillus?
The biology, taxonomy, and clinical fingerprint of Aspergillus — the foundation of how SCIT targets it.
Aspergillus fumigatus conidiophore — up to 50,000 conidia per conidiophore; thermotolerant growth from 20–50°C; average human inhales hundreds of conidia daily (Latgé JP, Clin Microbiol Rev 1999).
- Scientific name
- Aspergillus fumigatus (primary); A. niger; A. flavus
- Family
- AspergillaceaeEurotiales, Eurotiomycetes, Ascomycota
- Type
- Thermotolerant indoor and outdoor mold — perennial year-round exposure
- Native to
- Cosmopolitan; ubiquitous in soil, compost, decaying vegetation, and indoor environments worldwide
- Allergen proteins
- Asp f 1 (major) — 18 kDa ribotoxin; species-specific; 80% sensitivity for ABPA; marker of genuine A. fumigatus sensitizationAsp f 2 (major) — 37 kDa metalloprotease; differentiates ABPA from simple sensitizationAsp f 3 — 19 kDa peroxisomal protein; 93.3% sensitivity in CF patients; cross-reactiveAsp f 4 — 30 kDa; ABPA-specific; 99.2% specificity combined with Asp f 6Asp f 6 — 26.5 kDa MnSOD; ABPA-associated pan-allergen; cross-reactive with other fungi
- Particle size
- 2.5–3.0 µm — among the smallest allergenic fungal conidia; alveolar penetration documented
- Avoidance difficulty
- Very difficult
How Aspergillus Allergy Presents
Symptoms by body system — useful for distinguishing Aspergillus sensitivity from overlapping allergies and infections.
Respiratory
- ABPA hallmarks: wheezing, productive cough with brown mucus plugs, recurrent pulmonary infiltrates
- SAFS: severe refractory asthma with high total IgE and positive Aspergillus-specific IgE
- Allergic fungal sinusitis: nasal polyps, characteristic allergic mucin, chronically blocked sinuses
- Simple sensitization: seasonal or perennial rhinitis and mild-to-moderate asthma
- Chronic pulmonary aspergillosis: progressive cavitary lung disease in structurally abnormal lungs
Ocular
- Allergic conjunctivitis in simply-sensitized patients during high outdoor spore periods
- Periorbital edema in patients with concomitant rhinitis and ABPA
- Rare invasive orbital aspergillosis in severely immunocompromised patients (not allergic)
Dermal
- Eczema flares in atopic patients with Aspergillus sensitization
- Urticaria as part of systemic hypersensitivity in ABPA exacerbations
- Rare cutaneous aspergillosis in immunocompromised hosts — not IgE-mediated
Systemic
- ABPA exacerbations: fever, malaise, eosinophilia, elevated total IgE (typically >1,000 IU/mL)
- Pulmonary fibrosis in late-stage ABPA (ABPA-CPF) with irreversible lung damage
- Invasive aspergillosis in neutropenic or immunocompromised patients: 25–90% mortality
- Mast cell activation and elevated blood eosinophils as markers of ongoing ABPA inflammation
A patient with asthma and a positive Aspergillus IgE needs an ABPA workup before any conversation about shots — that means total IgE, eosinophil count, HRCT, and Asp f 4 and f 6 component testing. If total IgE is over 500 IU/mL and the components fit, we are in ABPA territory and the answer is not immunotherapy. It is prednisolone, itraconazole, and often omalizumab. SCIT without ruling out ABPA first is the wrong sequence.
Where Aspergillus Triggers Year-Round
Aspergillus is a perennial trigger — exposure is constant for sensitized patients. Geographic intensity still varies by climate.
12-Month Intensity
Year-roundYear-round indoor and outdoor exposure; outdoor peaks in warm months (compost, soil); indoor perennial via HVAC, potted plants, and damp materials· Perennial — thermotolerant growth from 20–50°C means exposure continues through winter indoors
US Exposure Map
7 high-intensity statesWhat Aspergillus Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Aspergillus fumigatus has the most complex cross-reactivity profile of any mold allergen — 30 IUIS-named proteins share sequences with Penicillium, Cladosporium, Alternaria, and Candida across multiple allergen families.
Pan-fungal enolase cross-reactivity (Cla h 6 / Asp f 22); Asp f 18 / Cla h 9 serine protease overlap
Asp f 13 / Pen ch 13 serine proteases at 42–49% amino acid identity; both Eurotiales; 80% co-sensitization rate in Chinese cohort (Shen HD 1999)
MnSOD (Asp f 6) cross-reactivity; Saccharomycetes MnSOD conserved across Ascomycota phyla
Is SCIT Right for Your Aspergillus Allergy?
This five-question assessment helps identify where you sit on the Aspergillus disease spectrum — from simple sensitization through SAFS to ABPA — and what step comes next.
How would you describe your asthma control related to Aspergillus exposure?
The Aspergillus SCIT Protocol
Aspergillus SCIT is off-label and rarely prescribed. When a specialist considers it for selected patients with confirmed simple sensitization and ABPA definitively excluded, Aspergillus extract must be in a mold-only vial separate from all pollen extracts (serine-protease degradation rule), and total IgE must be monitored — a rising total IgE during SCIT may indicate ABPA development.
For the rare patient where Aspergillus SCIT is considered by a specialist, buildup is more conservative than for pollen allergens given elevated systemic-reaction risk with mold extracts. Reactions almost always begin within about 30 minutes, so with at-home Aspergillus SCIT through Curex a prescribed epinephrine auto-injector is confirmed on hand and the prescribing allergist supervises your first dose and every dose change live over Zoom. ABPA must be excluded (total IgE less than 500 IU/mL, negative Asp f 4/f 6 components) before initiating buildup. Total IgE should be rechecked during the buildup phase — a rise to above 500 IU/mL would suggest evolving ABPA and should halt the protocol.
Maintenance phase continues with mold-only vial, separate from pollens. No DBPC-RCT defines an optimal maintenance dose for Aspergillus SCIT. Monitoring total IgE and clinical status for ABPA emergence is part of ongoing management.
Given the absence of long-term RCT data, durability of Aspergillus SCIT benefit is unknown. Decisions are individualized. If ABPA features emerge at any point, SCIT is typically stopped and ABPA treatment initiated.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Aspergillus SCIT
Aspergillus SCIT has essentially no controlled-trial evidence for standard allergic disease — the evidence base is for ABPA treatments (corticosteroids, itraconazole, biologics), not SCIT.
- Omalizumab — ABPA exacerbation reduction (best evidence for Aspergillus-related disease)65%Voskamp AL et al., JACI in Practice 2015 — pooled analysis of omalizumab in ABPA
- Itraconazole — ABPA remission rate at 4 months (first-line ABPA antifungal)55%Stevens DA et al., N Engl J Med 2000;342:756-762, N=55 asthmatics with ABPA
There is no meaningful SCIT efficacy data for Aspergillus — the bars above reflect the evidence-supported treatments for ABPA (the most serious Aspergillus-related allergic disease), not immunotherapy. AAAAI/ACAAI Practice Parameter does not endorse Aspergillus SCIT as standard care. A patient asking about Aspergillus allergy shots should first clarify whether they have simple sensitization, SAFS, or ABPA — the treatment pathway is very different for each.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Aspergillus SCIT Side Effects
Aspergillus SCIT carries the same mold-extract safety profile as other fungal allergens — elevated systemic-reaction risk compared to pollen SCIT — with the additional concern that ABPA itself can be exacerbated if the diagnosis was missed pre-treatment.
Local reactions
4 documentedSystemic reactions
4 documentedABPA is generally an exclusion criterion for Aspergillus SCIT. The 2024 ISHAM criteria (total IgE above 500 IU/mL, positive Asp f 4/f 6 components) must be checked before initiating any allergen immunotherapy with Aspergillus extract.
SCIT vs Alternatives for Aspergillus
For Aspergillus-related disease, the treatment choice depends critically on which disease entity is present — ABPA has an entirely different treatment algorithm from simple sensitization, and SCIT is not first-line for either.
| Criterion | SCIT | OmalizumabBest | Itraconazole | SLIT Drops |
|---|---|---|---|---|
| Effectiveness | No controlled trial evidence for standard allergic disease | Consistently reduces ABPA exacerbations (Voskamp 2015) | 55% ABPA remission at 4 months (Stevens 2000) | No high-quality trial data for Aspergillus |
| 5-yr cost | $3,500–$15,000 total | $15,000–$50,000/year (biologic) | $1,000–$5,000/year | Curex at-home SCIT is $129/month |
| Duration | 3–5 years | Indefinite in ABPA | 4 months initial; repeat as needed | 3–5 years typical |
| Convenience | Weekly then monthly visits | Monthly subcutaneous injection | Twice-daily oral capsules | Daily at-home drops |
| Safety | ABPA exacerbation risk if misdiagnosed | Well-studied in ABPA | Drug interactions; hepatotoxicity monitoring | Low systemic risk |
| Lasting effect | Unknown | Requires ongoing treatment | Recurrence common after stopping | Unknown for Aspergillus |
SCIT
OmalizumabBest
Itraconazole
SLIT Drops
For ABPA, omalizumab and itraconazole have the best evidence; SCIT is not appropriate. For simple Aspergillus sensitization with ABPA definitively excluded, Curex delivers Aspergillus SCIT as a self-administered weekly shot at home for $129/month all-inclusive — a personalized serum sterile-compounded to USP <797>, with a prescribed epinephrine auto-injector confirmed on hand and your first dose plus every dose change supervised live over Zoom by the prescribing allergist — though high-quality Aspergillus immunotherapy evidence is also lacking, and specialist evaluation to exclude ABPA must precede any immunotherapy.
What Aspergillus SCIT Actually Costs
Aspergillus SCIT may require additional documentation given off-label status; ABPA biologic treatments (omalizumab, mepolizumab) require prior authorization with documented ABPA diagnosis per ISHAM criteria. Most major insurers cover omalizumab for ABPA when IgE criteria are met — confirm prior authorization requirements with your allergist. Curex at-home IgE testing identifies specific aspergillus sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
Flat monthly subscription — includes consult, prescription, and at-home dosing for sublingual immunotherapy.
See if you qualifyStop guessing about your aspergillus allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Aspergillus SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
These are three distinct clinical conditions with different treatments. Simple Aspergillus sensitization means your IgE blood test is positive and you may have rhinitis or mild asthma triggered by Aspergillus exposure. Severe Asthma with Fungal Sensitization (SAFS) means you have poorly controlled asthma driven in part by fungal IgE, but your total IgE is below 1,000 IU/mL and you do not meet ABPA criteria — antifungals may help in this group. ABPA (Allergic Bronchopulmonary Aspergillosis) is a distinct immunological disease with total IgE typically above 500 IU/mL, eosinophilia, positive A. fumigatus-specific IgE and IgG, and often pulmonary infiltrates or bronchiectasis. ABPA requires corticosteroids, itraconazole, and often omalizumab — not allergy shots.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.